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Background:  Chronic  kidney  disease  (CKD)  is  closely  associated  with  a higher  risk  of  cardiovascular  dis-
ease. However,  whether  patients  with  acute  coronary  syndrome  (ACS)  and  CKD  are  at  increased  risk  for
long-term mortality  after  coronary  revascularization  remains  unknown.
Methods  and results:  Data  from  consecutive  patients  with  ACS  who  had  undergone  coronary  revasculari-
zation,  including  percutaneous  coronary  intervention  (PCI)  and  coronary  artery  bypass  surgery  (CABG)
were analyzed.  The  estimated  glomerular  ﬁltration  rate  (eGFR)  was  calculated  using  the  current  Japanese
equation  and  CKD  was  deﬁned  as  eGFR  < 60  mL/min/1.73  m2.  Among  375  enrolled  patients  with ACS,  75
(20.0%)  had  CKD.  During  a  follow-up  period  of 10.0  ± 3.4  years, the  total  number  of  deaths  was 80  (21.3%),
of which  36  (9.6%)  were  due  to cardiovascular  causes.  Kaplan–Meier  analysis  showed  that  the  presenceevascularization of  CKD  was  associated  with  a  signiﬁcant  increase  in  mortality  from  all  causes  (log-rank  test,  p <  0.001)
and  cardiovascular  mortality  (p < 0.001).  Cox  proportional-hazard  analysis  revealed  that  CKD  increased
the risk  of  mortality  with  a hazard  ratio  of  2.31  (95%  conﬁdence  interval  (CI): 1.25–4.29, p =  0.008)  and  of
cardiovascular  death  with  a hazard  ratio  of  3.76  (95%  CI: 1.60–8.80,  p =  0.002)  in patients  with  ACS.
Conclusions:  CKD  is a powerful  determinant  of  long-term  all-cause  and  cardiovascular  mortality  after
ACS.
2  Jap© 201
. Introduction
Chronic kidney disease (CKD) is a prevalent and widespread
isease that might be a focus of not only patients, but also of physi-
ians and of the healthcare system. CKD is closely associated with
 higher risk of cardiovascular disease (CVD), and the presence of
KD is a potent predictor of a worse prognosis among patients with
oronary artery disease [1–6]. Coronary revascularization therapy
ncluding percutaneous coronary intervention (PCI) and coronary
rtery bypass surgery (CABG) is being applied to a widening spec-
rum of patients, including those with CKD [7–10]. In addition,
atients with acute coronary syndrome (ACS) have higher mortality
han patients with stable angina and prognosis of ACS remains poor
espite therapeutic advances including coronary revascularization
11]. Accordingly, it is important to identify factors that might
∗ Corresponding author at: Department of Cardiology, Juntendo University, School
f Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.: +81 3 5802 1056;
ax:  +81 3 5689 0627.
E-mail addresses: ktmmy@med.juntendo.ac.jp,
tmmy@juntendo.ac.jp (K. Miyauchi).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.08.007anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
contribute to the poor prognosis in patients with ACS. Although
several studies have shown a harmful effect of CKD on short-
term clinical outcomes after coronary revascularization therapy
[3,12], whether patients with ACS and CKD are at increased long-
term (>10 years) risk for cardiovascular events after coronary
revascularization therapy has not been determined. Moreover,
the association between CKD based on glomerular ﬁltration rates
(GFRs) estimated using the current Japanese equation and long-
term prognosis has not yet been deﬁned [13]. Therefore, we
investigated the signiﬁcance of CKD on >10-year clinical outcomes
of patients with ACS who were treated with coronary revasculari-
zation therapy.
2. Methods
2.1. Patients and data collectionThis study is a retrospective analysis of prospectively gathered
data. The data from 375 consecutive patients who had under-
gone coronary revascularization, including percutaneous coronary
intervention (PCI) and coronary artery bypass surgery (CABG) at
vier Ltd. All rights reserved.
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larization with plain old balloon angioplasty and 189 (50.4%) with
CABG. Baseline and clinical event data were fully documented dur-
ing the follow-up period (mean 10.0 ± 3.4 years) for all of these
patients (Table 1). Patients with CKD were older and more likely
Table 1
Baseline characteristics.
Preserved eGFR
N = 300
CKD N = 75 p-Value
Age (years) 59.4 ± 8.8 63.6 ± 7.7 <0.001
Male, n (%) 228 (76.0) 67 (89.3) 0.018
BMI  (kg/m2) 23.3 ± 2.7 23.3 ± 2.6 0.904
Smoker, n (%) 216 (72.0) 60 (80.0) 0.208
Family history of CAD, n (%) 91 (30.3) 20 (26.7) 0.631
Diabetes mellitus, n (%) 111 (37.0) 33 (44.0) 0.326
Hypertension, n (%) 185 (61.7) 45 (60.0) 0.895
Total cholesterol (mg/dL) 218.5 ± 52.6 229.7 ± 46.2 0.090
HDL cholesterol (mg/dL) 43.6 ± 13.4 43.9 ± 12.4 0.864
Triglyceride (mg/dL) 155.2 ± 86.5 176.9 ± 97.6 0.081
Creatinine (mg/dL) 0.70 ± 0.16 1.26 ± 0.52 <0.001
eGFR (mL/min/1.73 m2) 97.7 ± 36.1 50.5 ± 11.1 <0.001
Hemoglobin (g/dL) 13.4 ± 1.5 13.0 ± 1.8 0.050
Atrial ﬁbrillation, n (%) 37 (12.3) 9 (12.0) 1.000
Prior stroke, n (%) 8 (2.7) 2 (2.7) 1.000
Prior MI,  n (%) 91 (30.3) 25 (33.3) 0.717
Multivessel disease, n (%) 199 (66.3) 52 (69.3) 0.721
LVEF (%) 64.0 ± 13.1 62.6 ± 13.2 0.407
Revascularization-isolated
PCI,  n (%)
180 (60.0) 43 (56.3) 0.772
Use  of arterial bypass graft,
n  (%)
61 (20.3) 9 (12.0) 0.136
Medication
ACE  inhibitors, n (%) 16 (5.3) 4 (5.3) 1.000
-Blocker, n (%) 66 (22.0) 23 (30.7) 0.115
Aspirin, n (%) 214 (71.3) 55 (73.3) 0.841
Warfarin, n (%) 94 (31.3) 22 (29.3) 0.845
Statins, n (%) 68 (22.7) 17 (22.7) 1.000T. Dohi et al. / Journal of 
untendo University Hospital (Tokyo, Japan) between January 1984
nd December 1992 were analyzed. We  enrolled patients with ACS
ho had undergone complete revascularization, deﬁned as the
bsence of bypassed major vessels with ≥50% stenosis, to min-
mize the inﬂuence of adverse outcomes related to incomplete
rocedures [14,15]. We  identiﬁed ACS among patients with acute
yocardial infarction (MI) and unstable angina. Acute MI  was  diag-
osed based on the presence of typical chest pain with ST-segment
levation on electrocardiograms or increased serum creatine kinase
evels. Unstable angina was diagnosed based on the presence of
haracteristic chest pain symptoms at rest associated with tran-
ient ischemic ST-segment shifts and normal serum creatine kinase
evels.
Patients on dialysis were excluded to identify the mortality risk
ssociated with CKD independently of dialysis. Patients with an
ntreated neoplasm at baseline and those with associated complex
ardiac procedures such as valve replacement or aneurysm repair
t the time of surgical revascularization, as well as those who were
ot Japanese were also excluded. Demographic data, including age,
ender, body mass index (BMI), coronary risk factors, medication
se, revascularization procedure-related factors, and comorbidities
ere collected from our institutional database.
Estimated GFR (eGFR) was obtained by using the following
peciﬁc equation for Japanese: GFR = 194 × [sCr]−1.094 × [Age]−0.287
×0.739 if female) [13]. We  deﬁned CKD as an
GFR < 60 mL/min/1.73 m2. This value is the generally accepted
utoff value for CKD and corresponds to CKD stages 3–5, accord-
ng to the National Kidney Foundation practice guidelines [16].
atients with eGFR ≥60 mL/min/1.73 m2 were not placed in the
roup without CKD because some of them might have had chronic
idney damage for ≥3 months despite having a higher eGFR. There-
ore, patients were assigned to a group with a preserved eGFR that
ncluded patients with eGFR ≥60 mL/min/1.73 m2, or a group with
KD, which included patients with eGFR < 60 mL/min/1.73 m2.
Hypertension was deﬁned as a systolic blood pressure
140 mmHg, a diastolic blood pressure ≥90 mmHg, or treatment
ith antihypertensive medication. Diabetes mellitus (DM) was
eﬁned as a fasting plasma glucose level ≥126 mg/dL or being under
reatment with oral hypoglycemic drugs or insulin injections. A cur-
ent smoker was deﬁned as a person who smoked at the time of
omplete revascularization or who had quit smoking within one
ear before complete revascularization. Patients with isolated PCI
ere those in whom complete revascularization was achieved by
CI without the need for bypass grafting.
Outcome data were collected by serial contact (every 5 years)
ith the patients or their families until September 2000. The med-
cal records of patients who died or who were treated at our hospital
ere analyzed. We  collected data for subjects who  discontinued
o be followed up at our institution by mailing or by telephone.
hen, information about the circumstances and date of death was
btained from the families of subjects who died at home, and details
f the cardiac events or the cause of death were supplied by other
ospitals or clinics where patients had been admitted. Mortality
ata were categorized as death from all causes or cardiovascular
eath including death from coronary artery disease, stroke, cardio-
enic shock, and sudden death.
This study was approved by the internal review board of
untendo University hospital, and proceeded according to the prin-
iples expressed in the Declaration of Helsinki and the ethics policy
f this institute.
.2. Statistical analysisContinuous variables are expressed as means ± SD. Normally
istributed variables were compared using Student’s t-test, and
he Mann–Whitney U test was used for non-parametric analyses.logy 60 (2012) 438–442 439
Categorical data were tabulated as frequencies and ratios, and were
compared using the Chi-square test or the Fisher exact test.
Survival was  compared between patients in the groups with CKD
and with preserved eGFR using the Kaplan–Meier estimate with
the log-rank test. Hazard ratios (HRs) of the CKD group were calcu-
lated using the Cox proportional hazards model. The assumption of
proportional hazards was  assessed using a log-minus-log survival
plot. Univariable analysis was based on the proportional hazards
model to determine the association between both all-cause and car-
diovascular deaths and the following variables: age, gender, BMI,
current smoker, DM,  hypertension, total and high density lipopro-
tein (HDL) cholesterol, triglyceride, hemoglobin, serum creatinine,
atrial ﬁbrillation, prior MI,  prior stroke, left ventricular ejection
fraction (LVEF), multivessel disease, use of an arterial bypass graft,
whether complete revascularization was  achieved by isolated PCI,
use of drugs, and the CKD group or the preserved eGFR group. Vari-
ables regarded as signiﬁcant (i.e. p ≤ 0.10) were included in the
multivariable analysis. Multivariable analyses veriﬁed the interac-
tions between each variable.
A p-value of <0.05 was considered statistically signiﬁcant, unless
otherwise indicated. All data were analyzed using SPSS version 11.0
for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Baseline characteristics and prevalence of factors
Among the 375 patients with ACS, 75 (20%) had CKD. In the
present study, 186 (49.6%) subjects underwent complete revascu-ACE, angiotensin-converting enzyme; BMI, body mass index; CAD, coronary artery
disease; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate;
HDL, high density lipoprotein; LVEF, left ventricular ejection fraction; MI,  myocardial
infarction; PCI, percutaneous coronary intervention.
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Fig. 1. Results of survival analysis. (A) All-cause death. Cumulative survival rates
were signiﬁcantly lower in patients with chronic kidney disease (CKD) (log-rank40 T. Dohi et al. / Journal of 
o be male than those with preserved eGFR. They also had a ten-
ency toward greater cholesterol and triglyceride levels and lower
emoglobin as compared with the group with preserved eGFR.
erum creatinine was greater and eGFR was lower in the CKD group
y deﬁnition. None of the other characteristics signiﬁcantly dif-
ered between two groups. None of the patients in either group had
een implanted with stents since all underwent PCI using balloon
ngioplasty.
.2. Univariable and multivariable analysis for all-cause and CV
ortality
Cardiovascular mortality accounted for 45% (n = 36) of the 80
21.3%) patients who died during long-term follow. Kaplan–Meier
nalysis showed that the presence of CKD at the time of revasculari-
ation was associated with a signiﬁcant increase in mortality from
ll causes and cardiovascular mortality (log-rank test: p < 0.001 for
oth) (Fig. 1A and B).
Table 2 shows the results of the univariable analysis for all-cause
eath. Variables that were associated with all-cause death were
ge, smoking history, serum creatinine level, hemoglobin level,
trial ﬁbrillation, prior MI,  multivessel disease, LVEF, and revas-
ularization achieved by isolated PCI in addition to the presence of
KD. Thus, these were included into multivariable analysis, which
evealed the presence of CKD is a signiﬁcant independent risk for
ll-cause mortality (hazard ratio (HR), 2.31; 95% conﬁdence inter-
al (CI), 1.25–4.29; p = 0.008) in addition to more advanced age
HR, 1.05; 95%CI, 1.02–1.08; p = 0.002), presence of atrial ﬁbrillation
HR, 2.24; 95%CI, 1.28–3.90; p = 0.004), prior MI  (HR, 1.95; 95%CI,
.09–3.47; p = 0.024), and multivessel disease (HR, 2.34; 95%CI,
.07–5.14; p = 0.034).
Table 3 also shows the results of the univariable analysis of car-
iovascular death. Variables in addition to the presence of CKD
hat were associated with cardiovascular death were serum lev-
ls of total cholesterol and creatinine, as well as atrial ﬁbrillation,
rior MI  and stroke, multivessel disease, and LVEF. These factors
ere included in the multivariable analysis. The ﬁndings showed
hat presence of CKD imposes a signiﬁcant independent risk for
ardiovascular mortality (HR, 3.76; 95%CI, 1.60–8.80; p = 0.002)
n addition to the presence of atrial ﬁbrillation (HR, 3.57; 95%CI,
.66–7.68; p = 0.001), and multivessel disease (HR, 3.17; 95%CI,
.06–9.53; p = 0.039).
. Discussion
The present study demonstrated that CKD was  signiﬁcantly
ssociated with the long-term clinical outcomes of ACS patients
fter complete coronary revascularization. Moreover, even after
djustment for important factors by multivariable Cox regression
odels, CKD remains a signiﬁcant predictor of negative long-term
linical outcomes after ACS. Finally, CKD was deﬁned based on eGFR
evels using the current equation for Japanese.
Impaired renal function is related to death and cardiovascular
vents in patients with ACS [17,18].  Several others also have identi-
ed CKD as a powerful independent predictor of adverse outcomes
fter PCI and CABG [3,19–21]. Additionally, studies of long-term
utcomes after ACS have revealed a negative effect of CKD on clin-
cal outcomes a few years after revascularization therapy, namely,
he follow-up limit of most studies [8,22–24]. Thus, we consider
hat our results not only conﬁrm the clinical impact of CKD in
atients with ACS after coronary revascularization therapy but also
how the clinical impact of CKD on long-term outcomes in patients
ith severe coronary artery disease. Indeed, survival rates for up to
 years were similar between the groups with preserved eGFR and
ith CKD, whereas mortality signiﬁcantly diverged during the latertest: p < 0.001) and (B) cardiovascular death: cumulative survival rates were sig-
niﬁcantly lower in patients with CKD (log rank test: p < 0.001). eGFR, estimated
glomerular ﬁltration rate.
phase (Fig. 1) and was very clear around 10 years. After adjustment
for important factors by multivariable Cox regression models, CKD
remained a signiﬁcant predictor of negative long-term clinical out-
comes after ACS. Consequently, we  believe that our ﬁndings clarify
the clinical signiﬁcance of even a moderate degree of impaired renal
function over the long term after ACS.
Several factors such as excess comorbidities, underuse of ben-
eﬁcial treatment strategies for secondary prevention, therapeutic
toxicity, and abnormal vascular pathology of CKD might contribute
to the relationship between CKD and worse outcomes [25]. In addi-
tion, coexisting conditions such as diabetes and hypertension, as
well as the presence of impaired renal function itself, can lead to
activation of the renin-angiotensin system, oxidative stress, ele-
vated asymmetric dimethylarginine, low-grade inﬂammation with
increased circulating cytokines and dyslipidemia, all of which play
signiﬁcant roles in relationships between impaired renal function
T. Dohi et al. / Journal of Cardiology 60 (2012) 438–442 441
Table  2
Risks for all-cause mortality in univariable and multivariable analyses.
Univariable Multivariable
HR 95% CI p-Value HR 95% CI p-Value
Age 1.06 1.03–1.09 <0.001 1.05 1.02–1.08 0.002
Male  sex 1.01 0.59–1.72 0.979 – – –
BMI  0.95 0.87–1.03 0.182 – – –
Hypertension 1.35 0.84–2.15 0.211 – – –
Diabetes mellitus 1.44 0.92–2.24 0.109 – – –
Total  cholesterol 1.00 099–1.01 0.292 – – –
Triglyceride 1.00 0.99–1.00 0.611 – – –
HDL  cholesterol 1.00 0.99–1.02 0.703 – – –
Current smoker 0.58 0.37–0.93 0.022 0.67 0.42–1.09 0.109
Family  history of CAD 1.30 0.82–2.06 0.272 – – –
Serum creatinine 1.80 1.18–2.75 0.006 1.20 0.60–2.41 0.607
CKD  2.64 1.66–4.19 <0.001 2.31 1.25–4.29 0.008
Hemoglobin 0.87 0.76–1.00 0.052 0.96 0.82–1.12 0.580
Atrial  ﬁbrillation 2.61 1.54–4.42 <0.001 2.24 1.28–3.90 0.004
Prior  MI  2.73 1.76–4.24 <0.001 1.95 1.09–3.47 0.024
Prior  stroke 2.04 0.64–6.49 0.228 – – –
Multivessel disease 3.50 1.80–6.79 <0.001 2.34 1.07–5.14 0.034
Use  of arterial bypass graft 0.72 0.38–1.37 0.321 – – –
LVEF 0.97 0.96–0.99 0.001 0.99 0.97–1.00 0.135
Revascularization-isolated PCI 2.24 1.31–3.84 0.003 0.93 0.45–1.93 0.853
Aspirin 0.86 0.54–1.38 0.536 – – –
ACE  inhibitors 1.43 0.58–3.54 0.442 – – –
Beta  blockers 1.08 0.65–1.78 0.768 – – –
Statins  0.71 0.37–1.35 0.298 – – –
H  lipop
i ventio
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HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; HDL, high density
nfarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary inter
nd cardiovascular events [26]. Furthermore, platelet dysfunc-
ion related to CKD and dosing errors of antithrombotic agents
an increase bleeding risk among CKD patients and contribute
o increased mortality [27]. Hence, we considered that we could
onﬁrm that CKD independently affects poor clinical outcomes in
atients with ACS over the long term. We  also believe that more
omprehensive intervention for impaired renal function from the
arly phase might be needed to improve the worse prognosis asso-
iated with CKD. This means that CKD should be recognized and
able 3
isks for cardiovascular mortality in univariable and multivariable analyses.
Univariable 
HR 95% CI 
Age 1.03 0.99–1.07 
Male  sex 1.36 0.57–3.27 
BMI  1.01 0.89–1.14 
Hypertension 1.68 0.81–3.48 
Diabetes mellitus 1.67 0.87–3.22 
Total  cholesterol 1.01 1.00–1.02 
Triglyceride 1.00 0.99–1.00 
HDL  cholesterol 0.99 0.96–1.01 
Current smoker 0.82 0.39–1.69 
Family history of CAD 0.99 0.48–2.05 
Serum creatinine 2.03 1.16–3.58 
CKD  3.29 1.67–6.48 
Hemoglobin 0.91 0.74–1.12 
Atrial  ﬁbrillation 3.72 1.79–7.74 
Prior  MI  1.99 1.03–3.84 
Prior  stroke 3.38 0.80–14.2 
Multivessel disease 4.00 1.41–11.3 
Use  of arterial bypass graft 0.90 0.37–2.18 
LVEF  0.97 0.95–0.99 
Revascularization-isolated PCI 1.77 0.83–3.80 
Aspirin 1.16 0.56–2.41 
ACE  inhibitors 1.28 0.31–5.35 
Beta  blockers 1.70 0.86–3.36 
Statins 0.71 0.27–1.86 
CE, angiotensin-converting enzyme; BMI, body mass index; CAD, coronary artery disease;
R,  hazard ratio; LVEF, left ventricular ejection fraction; MI,  myocardial infarction; PCI, protein; CAD, coronary artery disease; CKD, chronic kidney disease; MI, myocardial
n; ACE, angiotensin-converting enzyme.
treated in the early phase after an ACS episode or revasculariza-
tion procedures. A recent retrospective study investigated whether
advances in ACS management such as statins, anti-thrombotic
agents, and an early invasive approach have improved the prog-
nosis of patients with CKD [8]. One-year cardiovascular event rates
increased with decreasing baseline renal function, conﬁrming that
the prognosis of these patients remains poor despite contempo-
rary practice including an early invasive approach. A more recent
multicenter observational study demonstrated an independent
Multivariable
p-Value HR 95% CI p-Value
0.214 – – –
0.491 – – –
0.899 – – –
0.165 – – –
0.126 – – –
0.022 1.01 0.99–1.01 0.097
0.517 – – –
0.305 – – –
0.583 – – –
0.973 – – –
0.014 0.90 0.95–1.01 0.819
0.001 3.76 1.60–8.80 0.002
0.380 – – –
<0.001 3.57 1.66–7.68 0.001
0.039 1.11 0.53–2.32 0.777
0.097 1.55 0.34–7.16 0.575
0.009 3.17 1.06–9.53 0.039
0.817 – – –
0.013 0.98 0.95–1.01 0.112
0.138 – – –
0.698 – – –
0.738 – – –
0.130 – – –
0.489 – – –
 CI, conﬁdence interval; CKD, chronic kidney disease; HDL, high density lipoprotein;
ercutaneous coronary intervention.
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ssociation between in-hospital coronary revascularization and
mproved one-year survival, irrespective of eGFR [28]. Although
hese studies observed increased referral rates over consecutive
ears for in-hospital coronary angiography and revascularization
rrespective of renal dysfunction, patients with CKD continue to
e treated more conservatively, with an associated worse outcome
28,29]. Therefore, we believe that further prospective studies are
eeded to deﬁne an optimal ACS management strategy from the
arly phase in patients with CKD.
One limitation of the present study was that the presence of
tructural kidney disease was not determined in our study par-
icipants from ﬁndings such as abnormal ultrasound ﬁndings or
roteinuria. Therefore, we might not have accurately deﬁned and
valuated patients with CKD whose eGFR was >60 mL/min/1.73 m2.
owever, we consider that a simple separation determined by eGFR
s feasible for routine clinical practice, especially for the secondary
revention of coronary artery disease.
In conclusion, CKD was associated with higher long-term all-
ause and cardiovascular mortality after ACS. Moreover, CKD based
n eGFR determined using the current Japanese equation was  an
ndependent negative predictor of long-term survival even after
djustment for confounding variables. Early recognition and treat-
ent for CKD should be considered as a means of secondary
revention of coronary artery disease after successful coronary
evascularization therapy in patients with ACS.
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